Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2022 > Synthetic peptide acts on endocannabinoid system to combat obesity

Synthetic peptide acts on endocannabinoid system to combat obesity

Synthetic peptide acts on endocannabinoid system to combat obesity

Read also

FDA approves Roche’s Gazyva for lupus nephritis

FDA approves Roche’s Gazyva for lupus nephritis

The US Food and Drug Administration (FDA) has granted approval for Roche’s Gazyva/ Gazyvaro (obinutuzumab) to treat adult patients with active lupus nephritis (LN) who are on...

Acquisition strengthens Aspire Pharma’s strategic portfolio

Acquisition strengthens Aspire Pharma’s strategic portfolio

Aspire Pharma, a rapidly growing UK-based specialty generics business, has announced the acquisition of Charlwood Pharma, a privately-owned company specializing in the research and development of nich...

iBio to Present New Preclinical Data

iBio to Present New Preclinical Data

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

FDA approves Glaukos’ Epioxa

FDA approves Glaukos’ Epioxa

FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment